Cargando…

Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer’s Disease

One of the major histopathological hallmarks of Alzheimer’s disease (AD) is cerebral deposits of extracellular β-amyloid peptides. Preclinical studies have pointed to glucagon-like peptide 1 (GLP-1) receptors as a potential novel target in the treatment of AD. GLP-1 receptor agonists, including exen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hansen, Henrik H., Fabricius, Katrine, Barkholt, Pernille, Kongsbak-Wismann, Pernille, Schlumberger, Chantal, Jelsing, Jacob, Terwel, Dick, Termont, Annelies, Pyke, Charles, Knudsen, Lotte Bjerre, Vrang, Niels
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946784/ https://www.ncbi.nlm.nih.gov/pubmed/27421117 http://dx.doi.org/10.1371/journal.pone.0158205

Ejemplares similares

The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer’s Disease
por: Hansen, Henrik H., et al.
Publicado: (2015)

Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
por: Madsen, Mette Simone Aae, et al.
Publicado: (2019)

Application of the Physical Disector Principle for Quantification of Dopaminergic Neuronal Loss in a Rat 6-Hydroxydopamine Nigral Lesion Model of Parkinson's Disease
por: Fabricius, Katrine, et al.
Publicado: (2017)

Activation of the renal GLP‐1R leads to expression of Ren1 in the renal vascular tree
por: Bjørnholm, Katrine Dahl, et al.
Publicado: (2021)

Quantitative whole-brain 3D imaging of tyrosine hydroxylase-labeled neuron architecture in the mouse MPTP model of Parkinson's disease
por: Roostalu, Urmas, et al.
Publicado: (2019)

Distribution and ultrastructural localization of the glucagon-like peptide-1 receptor (GLP-1R) in the rat brain
por: Farkas, Erzsébet, et al.
Publicado: (2020)

The Human GLP-1 Analog Liraglutide and the Pancreas: Evidence for the Absence of Structural Pancreatic Changes in Three Species
por: Nyborg, Niels C.B., et al.
Publicado: (2012)

The endogenous preproglucagon system is not essential for gut growth homeostasis in mice
por: Wismann, Pernille, et al.
Publicado: (2017)

Alterations in hypothalamic gene expression following Roux-en-Y gastric bypass
por: Barkholt, Pernille, et al.
Publicado: (2016)

Long‐acting glucagon‐like peptide‐1 receptor agonists have direct access to and effects on pro‐opiomelanocortin/cocaine‐ and amphetamine‐stimulated transcript neurons in the mouse hypothalamus
por: Knudsen, Lotte Bjerre, et al.
Publicado: (2016)

The Discovery and Development of Liraglutide and Semaglutide
por: Knudsen, Lotte Bjerre, et al.
Publicado: (2019)

The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE(−/−) and LDLr(−/−) Mice by a Mechanism That Includes Inflammatory Pathways
por: Rakipovski, Günaj, et al.
Publicado: (2018)

Comment on: Butler et al. A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 Therapies Safe? Diabetes Care 2013;36:2118–2125
por: Bjerre Knudsen, Lotte, et al.
Publicado: (2013)

Glucagon, GLP-1 and Thermogenesis
por: González-García, Ismael, et al.
Publicado: (2019)

Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension
por: Helmstädter, Johanna, et al.
Publicado: (2020)

Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor
por: Underwood, Christina Rye, et al.
Publicado: (2010)

Glucagon‐like peptide‐1 receptor expression in the human eye
por: Hebsgaard, Josephine B., et al.
Publicado: (2018)

Glucagon-like peptide 1 (GLP-1)
por: Müller, T.D., et al.
Publicado: (2019)

Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation through a Calcium and AMPK Dependent Mechanism
por: Krasner, Nadia M., et al.
Publicado: (2014)

PM426. Effect of a glucagon-like peptide 1 (GLP-1) receptor agonist, liraglutide, on cognition and body weight during antipsychotic treatment
por: Babic, I, et al.
Publicado: (2016)

A Hamster Model of Diet-Induced Obesity for Preclinical Evaluation of Anti-Obesity, Anti-Diabetic and Lipid Modulating Agents
por: Dalbøge, Louise S., et al.
Publicado: (2015)

An Optimized Mouse Brain Atlas for Automated Mapping and Quantification of Neuronal Activity Using iDISCO+ and Light Sheet Fluorescence Microscopy
por: Perens, Johanna, et al.
Publicado: (2020)

Allosteric Modulation of the Activity of the Glucagon-like Peptide-1 (GLP-1) Metabolite GLP-1 9–36 Amide at the GLP-1 Receptor
por: Li, Naichang, et al.
Publicado: (2012)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide
por: Flint, Anne, et al.
Publicado: (2010)

Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea
por: Kårhus, Martin Lund, et al.
Publicado: (2022)

Whole-brain activation signatures of weight-lowering drugs
por: Hansen, Henrik H., et al.
Publicado: (2021)

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes
por: Fujishima, Yuya, et al.
Publicado: (2012)

Chronic Administration of the Glucagon-Like Peptide-1 Analog, Liraglutide, Delays the Onset of Diabetes and Lowers Triglycerides in UCD-T2DM Rats
por: Cummings, Bethany P., et al.
Publicado: (2010)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

GLP-1/glucagon receptor co-agonism for treatment of obesity
por: Sánchez-Garrido, Miguel A., et al.
Publicado: (2017)

Protective effect of GLP-1 analog liraglutide on podocytes in mice with diabetic nephropathy
por: Shi, Shaomin, et al.
Publicado: (2023)

Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study
por: Inoue, Kana, et al.
Publicado: (2014)

Serum levels of glucagon-like peptide (GLP)-1 and GLP-2 in patients with Hashimoto's thyroiditis
por: Jin, Yue, et al.
Publicado: (2015)

The Imaging of Insulinomas Using a Radionuclide-Labelled Molecule of the GLP-1 Analogue Liraglutide: A New Application of Liraglutide
por: Lv, Jing, et al.
Publicado: (2014)

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
por: Saraiva, Francisco Kerr, et al.
Publicado: (2014)

Modulation of Cardiac Ventricular Excitability by GLP-1 (Glucagon-Like Peptide-1)
por: Ang, Richard, et al.
Publicado: (2018)

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
por: Ja’arah, Daria, et al.
Publicado: (2021)

Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis
por: Sawada, Noritaka, et al.
Publicado: (2020)

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Liraglutide Alters Bone Marrow Exosome-Mediated miRNA Signal Pathways in Ovariectomized Rats with Type 2 Diabetes
por: Li, Jin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_b936d0nuns2m9r8narru6c5l6v